March 30, 2026 · Form 4 insider transaction
Brady James Aloysius sold 10,834 shares of Xeris Biopharma Holdings, Inc. at $5.54 per share, a transaction worth $60.0K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.; The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.290 to $5.630, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.